BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gitto S, Villa E. Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome after Liver Transplant. Int J Mol Sci. 2016;17:490. [PMID: 27049380 DOI: 10.3390/ijms17040490] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Cao YN, Baiyisaiti A, Wong CW, Hsu SH, Qi R. Polyurethane Nanoparticle-Loaded Fenofibrate Exerts Inhibitory Effects on Nonalcoholic Fatty Liver Disease in Mice. Mol Pharm 2018;15:4550-7. [PMID: 30188729 DOI: 10.1021/acs.molpharmaceut.8b00548] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
2 Whitsett M, Serper M. Exercise Interventions for Transplant Recipients. Curr Transpl Rep 2021;8:111-7. [DOI: 10.1007/s40472-021-00324-3] [Reference Citation Analysis]
3 Eshraghian A, Nikeghbalian S, Kazemi K, Shamsaeefar A, Geramizadeh B, Malek-Hosseini SA. Non-alcoholic fatty liver disease after liver transplantation in patients with non-alcoholic steatohepatitis and cryptogenic cirrhosis: the impact of pre-transplant graft steatosis. HPB (Oxford) 2020;22:521-8. [PMID: 31431413 DOI: 10.1016/j.hpb.2019.07.015] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Hu LS, Chai YC, Zheng J, Shi JH, Zhang C, Tian M, Lv Y, Wang B, Jia A. Warm ischemia time and elevated serum uric acid are associated with metabolic syndrome after liver transplantation with donation after cardiac death. World J Gastroenterol 2018; 24(43): 4920-4927 [PMID: 30487701 DOI: 10.3748/wjg.v24.i43.4920] [Reference Citation Analysis]
5 Mikolasevic I, Filipec-Kanizaj T, Mijic M, Jakopcic I, Milic S, Hrstic I, Sobocan N, Stimac D, Burra P. Nonalcoholic fatty liver disease and liver transplantation - Where do we stand? World J Gastroenterol 2018; 24(14): 1491-1506 [PMID: 29662288 DOI: 10.3748/wjg.v24.i14.1491] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 43] [Article Influence: 12.5] [Reference Citation Analysis]
6 Sanchez-Torrijos Y, Ampuero J, Romero-Gómez M. Cardiovascular assessment in liver transplant for non-alcoholic steatohepatitis patients: What we do, what we should do. World J Hepatol 2017; 9(15): 697-703 [PMID: 28596817 DOI: 10.4254/wjh.v9.i15.697] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
7 Norrman AE, Tervahartiala T, Sahlberg E, Sorsa T, Ruokonen H, Grönroos L, Meurman JH, Isoniemi H, Nordin A, Åberg F, Helenius-Hietala J. Salivary Biomarkers and Oral Health in Liver Transplant Recipients, with an Emphasis on Diabetes. Diagnostics (Basel) 2021;11:662. [PMID: 33916950 DOI: 10.3390/diagnostics11040662] [Reference Citation Analysis]
8 Russo MW. The Care of the Postliver Transplant Patient. J Clin Gastroenterol 2017;51:683-92. [PMID: 28796003 DOI: 10.1097/MCG.0000000000000886] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
9 Ahmed M, Ahmed MH. Nonalcoholic fatty liver disease and COVID-19: An epidemic that begets pandemic. World J Clin Cases 2021; 9(17): 4133-4142 [PMID: 34141776 DOI: 10.12998/wjcc.v9.i17.4133] [Reference Citation Analysis]
10 Maiwall R, Gupta M. Peri-transplant renal dysfunction in patients with non-alcoholic steatohepatitis undergoing liver transplantation. Transl Gastroenterol Hepatol 2020;5:18. [PMID: 32258522 DOI: 10.21037/tgh.2019.10.11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Benedict M, Zhang X. Non-alcoholic fatty liver disease: An expanded review. World J Hepatol 2017; 9(16): 715-732 [PMID: 28652891 DOI: 10.4254/wjh.v9.i16.715] [Cited by in Crossref: 304] [Cited by in F6Publishing: 267] [Article Influence: 60.8] [Reference Citation Analysis]
12 Pisano G, Fracanzani AL, Caccamo L, Donato MF, Fargion S. Cardiovascular risk after orthotopic liver transplantation, a review of the literature and preliminary results of a prospective study. World J Gastroenterol 2016; 22(40): 8869-8882 [PMID: 27833378 DOI: 10.3748/wjg.v22.i40.8869] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
13 Gitto S, Marra F, De Maria N, Bihl F, Villa E, Andreone P, Burra P. Nonalcoholic steatohepatitis before and after liver transplant: keeping up with the times. Expert Review of Gastroenterology & Hepatology 2018;13:173-8. [DOI: 10.1080/17474124.2019.1551132] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Lonardo A, Targher G. NAFLD: Is There Anything New under the Sun? Int J Mol Sci 2017;18:E1955. [PMID: 28895919 DOI: 10.3390/ijms18091955] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
15 Mikolasevic I, Stojsavljevic S, Blazic F, Mijic M, Radic-Kristo D, Juric T, Skenderevic N, Klapan M, Lukic A, Filipec Kanizaj T. Noninvasive markers of liver steatosis and fibrosis after liver transplantation – Where do we stand? World J Transplant 2021; 11(3): 37-53 [PMID: 33816145 DOI: 10.5500/wjt.v11.i3.37] [Reference Citation Analysis]
16 Hu R, Liu S, Anwaier G, Wang Q, Shen W, Shen Q, Qi R. Formulation and intestinal absorption of naringenin loaded nanostructured lipid carrier and its inhibitory effects on nonalcoholic fatty liver disease. Nanomedicine 2021;32:102310. [PMID: 33184021 DOI: 10.1016/j.nano.2020.102310] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
17 Cao YN, Yue SS, Wang AY, Xu L, Hu YT, Qiao X, Wu TY, Ye M, Wu YC, Qi R. Antrodia cinnamomea and its compound dehydroeburicoic acid attenuate nonalcoholic fatty liver disease by upregulating ALDH2 activity. J Ethnopharmacol 2022;:115146. [PMID: 35304272 DOI: 10.1016/j.jep.2022.115146] [Reference Citation Analysis]
18 Peláez-Jaramillo MJ, Cárdenas-Mojica AA, Gaete PV, Mendivil CO. Post-Liver Transplantation Diabetes Mellitus: A Review of Relevance and Approach to Treatment. Diabetes Ther 2018;9:521-43. [PMID: 29411291 DOI: 10.1007/s13300-018-0374-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]